There are 2789 resources available
1262P - ROS1 resistance mutations and co-occurring genetic alterations to the ROS1 protein-tyrosine kinase inhibitors (crizotinib) in lung cancer
Presenter: Yuqing Weng
Session: ePoster Display
1338P - A phase III study comparing BCD-021, a bevacizumab biosimilar, and reference bevacizumab in patients with stage IIIB or IV non-squamous NSCLC
Presenter: Natalia Fadeeva
Session: ePoster Display
1308P - Efficacy and safety of anti-PD-1 therapy plus anlotinib in previously treated advanced NSCLC
Presenter: Xin Lv
Session: ePoster Display
1309P - A multicenter phase I study of radium-223 (Ra-223) plus pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC)
Presenter: Martin Reck
Session: ePoster Display
1310P - Toripalimab combined with chemotherapy as second-line treatment of advanced non-small cell lung cancer (NSCLC): A single center retrospective study
Presenter: man Jiang
Session: ePoster Display
1311P - The role of inflammatory biomarkers in advanced non-small cell lung cancer patients treated with chemo-immunotherapy
Presenter: Emma Zattarin
Session: ePoster Display
1312P - Prognostic impact of KRAS status in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor monotherapy
Presenter: Giacomo Pelizzari
Session: ePoster Display
1314P - Preliminary results of sequential combination of immunotherapy followed by chemotherapy in advanced non-small cell lung cancer
Presenter: Luc Heraudet
Session: ePoster Display